Laure Elens

List of Publications by Year
in descending order

74 papers	3,419 citations	159585 30 h-index	149698 56 g-index
74 all docs	74 docs citations	74 times ranked	3274 citing authors

#	Article	IF	Citations
1	Atorvastatin population pharmacokinetics in a realâ€life setting: Influence of genetic polymorphisms and association with clinical response. Clinical and Translational Science, 2022, 15, 667-679.	3.1	8
2	HYGIEIA: HYpothesizing the Genesis of Infectious Diseases and Epidemics through an Integrated Systems Biology Approach. Viruses, 2022, 14, 1373.	3.3	2
3	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. Antibiotics, 2022, 11, 898.	3.7	4
4	Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations. Clinical Pharmacokinetics, 2021, 60, 177-189.	3.5	4
5	Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model. European Journal of Clinical Pharmacology, 2021, 77, 607-616.	1.9	1
6	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	2.0	89
7	Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines. Scientific Reports, 2021, 11, 9000.	3.3	1
8	CYP3A4âˆ—22 Genotyping in Clinical Practice: Ready for Implementation?. Frontiers in Genetics, 2021, 12, 711943.	2.3	32
9	Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 769-782.	3.3	19
10	The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients. Expert Review of Precision Medicine and Drug Development, 2020, 5, 313-316.	0.7	4
11	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drugâ€“Drug Interactions. Therapeutic Drug Monitoring, 2020, 42, 360-368.	2.0	48
12	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	2.0	374
13	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. British Journal of Clinical Pharmacology, 2019, 85, 601-615.	2.4	56
14	Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype. Pharmacogenomics, 2018, 19, 305-310.	1.3	7
15	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thrombosis Journal, 2018, 16, 28.	2.1	63
16	Cytochrome P450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. Pharmacogenomics, 2018, 19, 1097-1099.	1.3	0
17	Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 601-611.	3.3	6
18	Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines. Scientific Reports, 2018, 8, 10514.	3.3	12

#	Article	IF	Citations
19	Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. Scientific Reports, 2018, 8, 7359.	3.3	18
20	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. Clinical Pharmacokinetics, 2017, 56, 963-975.	3.5	69
21	The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenetics and Genomics, 2017, 27, 313-322.	1.5	52
22	Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. Pharmacogenomics, 2017, 18, 1133-1142.	1.3	22
23	Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?. Pharmacogenomics, 2017, 18, 1473-1480.	1.3	19
24	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Frontiers in Pharmacology, 2017, 8, 358.	3.5	44
25	SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. Therapeutic Drug Monitoring, 2016, 38, 487-492.	2.0	20
26	Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation. Therapeutic Drug Monitoring, 2016, 38, 525-533.	2.0	24
27	Impact of ABCB1 1236Câ€‰>â€‰T-2677Gâ€‰>â€‰T-3435Câ€‰>â€‰T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. Scientific Reports, 2016, 6, 29559.	3.3	31
28	ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. Pharmacogenomics, 2016, 17, 883-890.	1.3	22
29	Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LCâ€“MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drugâ€“drug interaction. Clinical Biochemistry, 2016, 49, 580-586.	1.9	16
30	Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism. PLoS ONE, 2016, 11, e0165631.	2.5	11
31	No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Drug Metabolism and Personalized Therapy, 2015, 30, 43-48.	0.6	16
32	The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics Journal, 2015, 15, 144-152.	2.0	46
33	Association of CYP3A variants with kidney transplant outcomes. Renal Failure, 2015, 37, 562-566.	2.1	9
34	Dental Apical Papilla as Therapy for Spinal Cord Injury. Journal of Dental Research, 2015, 94, 1575-1581.	5.2	45
35	Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Pharmacogenomics, 2014, 15, 1589-1597.	1.3	27
36	CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, 60-63.	1.2	30

#	Article	IF	Citations
37	Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 71-79.	2.0	81
38	POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics, 2014, 15, 1963-1972.	1.3	17
39	Influence of donorâ€"recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics, 2014, 15, 1207-1221.	1.3	29
40	Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. Pharmacogenomics, 2014, 15, 1287-1295.	1.3	29
41	Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients. Molecular Diagnosis and Therapy, 2014, 18, 323-31.	3.8	11
42	The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation. Clinical Pharmacokinetics, 2014, 53, 123-139.	3.5	186
43	Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. British Journal of Clinical Pharmacology, 2014, 77, 715-728.	2.4	40
44	ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines. PLoS ONE, 2014, 9, e91555.	2.5	38
45	CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics, 2013, 14, 137-149.	1.3	51
46	Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenomics, 2013, 14, 1295-1304.	1.3	15
47	The <scp>CYP</scp>3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. British Journal of Clinical Pharmacology, 2013, 75, 1545-1547.	2.4	35
48	CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics, 2013, 14, 1027-1036.	1.3	49
49	CYP3A4*22: promising newly identifiedCYP3A4variant allele for personalizing pharmacotherapy. Pharmacogenomics, 2013, 14, 47-62.	1.3	178
50	A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform. Clinical Cancer Research, 2013, 19, 5210-5217.	7.0	23
51	Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation. Therapeutic Drug Monitoring, 2013, 35, 608-616.	2.0	71
52	Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-Î± are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenetics and Genomics, 2013, 23, 649-657.	1.5	30
53	CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clinical Cancer Research, 2013, 19, 3316-3324.	7.0	88
54	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics, 2013, 23, 148-155.	1.5	35

#	Article	IF	Citations
55	The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenetics and Genomics, 2012, 22, 373-380.	1.5	73
56	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. Clinical Cancer Research, 2012, 18, 4433-4440.	7.0	80
57	191 Morphine Premedication for Intubation in Preterm Infants - A Pharmacokinetic and Pharmacogenetic Report. Archives of Disease in Childhood, 2012, 97, A55-A55.	1.9	0
58	Mycophenolic Acid-Related Anemia and Leucopenia in Renal Transplant Recipients Are Related to Genetic Polymorphisms in CYP2C8. Transplantation, 2012, 93, e39-e40.	1.0	13
59	Impact of CYP3A4*22 Allele on Sirolimus Dose Requirement in Kidney Transplant Patients. Transplantation, 2012, 94, 575.	1.0	2
60	Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. Journal of Surgical Research, 2012, 178, 988-995.	1.6	17
61	Pharmacogenetics in Kidney Transplantation. Molecular Diagnosis and Therapy, 2012, 16, 331-345.	3.8	18
62	Influence of Drug Exposure and Genetic Variation on Paclitaxelâ€“Induced Neurotoxicity. Annals of Oncology, 2012, 23, ix534.	1.2	1
63	Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitorsâ€™ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics, 2011, 12, 1383-1396.	1.3	139
64	A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients. Clinical Chemistry, 2011, 57, 1574-1583.	3.2	211
65	Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study. Pharmacogenetics and Genomics, 2011, 21, 861-866.	1.5	97
66	Functional defect caused by the 4544G>A SNP in ABCC2. Pharmacogenetics and Genomics, 2011, 21, 884-893.	1.5	29
67	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics, 2010, 11, 703-714.	1.3	97
68	Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics, 2010, 11, 1223-1234.	1.3	53
69	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics, 2009, 10, 1589-1597.	1.3	28
70	Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow up. Aids, 2009, 23, 1291-1293.	2.2	0
71	Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1805-1814.	2.3	31
72	Quantification of 8 HIV-Protease Inhibitors and 2 Nonnucleoside Reverse Transcriptase Inhibitors by Ultra-Performance Liquid Chromatography with Diode Array Detection. Clinical Chemistry, 2009, 55, 170-174.	3.2	19

#	Article	IF	Citations
73	1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenetics and Genomics, 2007, 17, 873-883.	1.5	94
74	CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study. American Journal of Transplantation, 2006, 6, 2706-2713.	4.7	160